HiberCell, Inc. has acquired the Imprime PGG program from Biothera Pharmaceuticals, Inc.
This website will deactivate on August 31. To learn more visit HiberCell.com

Tag: pembrolizumab

Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations Set for November 8 and 9 at Society for Immunotherapy of Cancer (SITC) Annual Meeting EAGAN, MN — November 5, 2019 — Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in triple negative breast cancer and melanoma this week at the Society for Immunotherapy of Cancer annual meeting in the Gaylord...

Read More

Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

Study to combine therapies in patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) EAGAN, MN — February 23, 2017 — Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in combination with the Merck (known as MSD outside the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with...

Read More